E. Ohman J or Asset Management AB Invests $741,000 in United Therapeutics Corporation $UTHR

E. Ohman J or Asset Management AB purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,521 shares of the biotechnology company’s stock, valued at approximately $741,000.

Other institutional investors have also recently added to or reduced their stakes in the company. WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB increased its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. Abich Financial Wealth Management LLC purchased a new stake in shares of United Therapeutics during the third quarter worth approximately $44,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several recent research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. TD Cowen raised their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $549.91.

United Therapeutics Price Performance

United Therapeutics stock opened at $541.60 on Thursday. The stock’s 50 day moving average price is $493.58 and its 200 day moving average price is $471.33. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $549.50. The company has a market cap of $23.74 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter in the prior year, the business posted $6.19 earnings per share. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Several brokerages have lifted price targets and reiterated buy/outperform views (examples cited include HC Wainwright, RBC, Cantor Fitzgerald and UBS), supporting upside expectations and helping sentiment. Analyst Coverage Summary
• Positive Sentiment: Wells Fargo published a bullish forecast for UTHR, calling for meaningful price appreciation and adding directional support to the tape. Wells Fargo Research
• Positive Sentiment: Recent quarterly results showed EPS outperformance versus consensus (EPS beat), underpinning the fundamental case even as revenue slightly missed; analysts’ upward revisions follow those results. Quarterly Results Summary
• Neutral Sentiment: Brokerage consensus remains a “Moderate Buy” — constructive but not unanimous; this keeps expectations elevated but measured. Analyst Consensus
• Neutral Sentiment: Institutional ownership is high and several funds reported increasing stakes in recent quarters, which can support liquidity and reduce volatility. Institutional Holdings
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in March; large officer sales can pressure sentiment even if company says sales are routine. SEC filings: CEO sale CEO SEC Filing, CFO sale CFO SEC Filing
• Neutral Sentiment: Short-interest reports in recent feeds show data anomalies (zero reported shares / NaN changes) and are not providing a clear short-squeeze or bearish signal at this time. Short Interest Data

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $479.51, for a total transaction of $10,788,975.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 336,820 shares of company stock valued at $166,359,058 in the last ninety days. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.